NICE (UK) terminated appraisal for Skyclarys (omaveloxolone) for treating Friedreich’s ataxia in people 16 years and over – Biogen

NICE (UK): NICE is unable to make a recommendation on omaveloxolone (Skyclarys) for treating Friedreich’s ataxia in people 16 years and over.

This is because Biogen withdrew its evidence submission.

NICE will review this decision if Biogen decides to make a new submission.